SLNO vs MDGL vs RYTM vs ARWR

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus 45. 8% for Rhythm Pharmaceuticals, Inc. (RYTM). Soleno Therapeutics, Inc. (SLNO) offers the better valuation at 135. 8x trailing P/E (13. 4x forward), making it the more compelling value choice. Analysts rate Soleno Therapeutics, Inc. (SLNO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Rhythm Pharmaceuticals, Inc.

(RYTM) delivered a total return of +335. 0%, compared to -36. 4% for Soleno Therapeutics, Inc. (SLNO). Over 10 years, the gap is even starker: MDGL returned +39. 2% versus SLNO's -87. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Madrigal Pharmaceuticals, Inc.

(MDGL) is the lower-risk stock at 0. 57β versus Arrowhead Pharmaceuticals, Inc. 's 1. 81β — meaning ARWR is approximately 220% more volatile than MDGL relative to the S&P 500. On balance sheet safety, Soleno Therapeutics, Inc. (SLNO) carries a lower debt/equity ratio of 1% versus 177% for Rhythm Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus 45. 8% for Rhythm Pharmaceuticals, Inc. (RYTM). On earnings-per-share growth, the picture is similar: Soleno Therapeutics, Inc. grew EPS 108. 9% year-over-year, compared to 28. 3% for Rhythm Pharmaceuticals, Inc.. Over a 3-year CAGR, RYTM leads at 100. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Soleno Therapeutics, Inc.

(SLNO) is the more profitable company, earning 11. 0% net margin versus -103. 6% for Rhythm Pharmaceuticals, Inc. — meaning it keeps 11. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARWR leads at 11. 9% versus -101. 2% for RYTM. At the gross margin level — before operating expenses — SLNO leads at 98. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SLNO: 51.

1% to $80. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57)). Both have compounded well over 10 years (MDGL: +39. 2%, SLNO: -87. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SLNO is a small-cap quality compounder stock; MDGL is a mid-cap high-growth stock; RYTM is a small-cap high-growth stock; ARWR is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.